Paper Details

  1. Home
  2. Paper Details

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Author: BoseAnjana, ChenChangzheng, GommollCarl P, GreenbergWilliam M, SambunarisAngelo, SheehanDavid V

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Levomilnacipran extended release (ER) is a serotonin and norepinephrine reuptake inhibitor that showed significant improvement in symptoms of major depressive disorder compared to placebo.
Paper Details　
Original Abstract of the Article :
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. This phase III study (NCT01034462) evaluated the efficacy, the safety, and the tolerability of 40 to 120 mg/d of levomiln...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047313/

データ提供：米国国立医学図書館（NLM）

Levomilnacipran for Major Depressive Disorder: A New Path in the Desert

Major Depressive Disorder (MDD) is a significant mental health concern, and finding effective treatments is a priority. This study investigates the efficacy and safety of levomilnacipran extended-release (ER), a serotonin and norepinephrine reuptake inhibitor, for treating MDD. The researchers conducted a phase III, double-blind, placebo-controlled, flexible-dose study to evaluate the effectiveness of levomilnacipran ER in patients with MDD.

The study found that levomilnacipran ER was significantly more effective than placebo in reducing symptoms of MDD, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Sheehan Disability Scale. However, the study also noted that levomilnacipran ER was associated with a higher incidence of adverse events compared to placebo.

Levomilnacipran ER: A Potential Option

This study suggests that levomilnacipran ER may be a viable treatment option for MDD. However, it's important to consider the potential side effects and discuss them with a healthcare professional. Finding the right treatment for MDD is like finding the right path through a vast desert; it's essential to navigate carefully and consider all aspects of the journey.

Managing Mental Health

If you're struggling with MDD, seeking professional help is crucial. There are various treatment options available, including psychotherapy, medication, and lifestyle changes. Remember, your mental health is just as important as your physical health; taking care of both is essential for a fulfilling life.

Dr.Camel's Conclusion

This study emphasizes the importance of finding effective and safe treatment options for MDD. Levomilnacipran ER offers a potential path forward, but it's important to approach treatment with a balanced perspective, considering both potential benefits and risks. The desert of mental health research continues to expand, and finding the right oasis for each individual is a journey that requires careful consideration and collaboration with healthcare professionals.

Date :
  1. Date Completed 2014-08-29
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

24172209

DOI: Digital Object Identifier

PMC4047313

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.